Preclinical Humanized PD-1 Mouse Model

Humanized Immune Checkpoint Mouse Models

Design of the hPD‑1 mouse

The humanized PD‑1 mouse model (hPD-1) has been developed by inserting, within the mouse PD-1 locus, a chimeric PD-1 with a human extracellular domain, a murine transmembrane domain and a murine intracellular domain.

Applications in immuno-oncology

The hPD-1 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 in fully immunocompetent mice.

Humanized tumor cell line MC38-hPD-L1:
Use our hPD-1 mouse model together with our cell line MC38-hPD-L1 as a syngeneic tumor model for testing the efficacy of combination therapies targeting human PD-1 and human PD-L1.

hPD-1 mice were crossed with hVISTA mice (hPD-1/hVISTA):
This double humanized hPD1/hVISTA model enables assessment of both compounds targeting human PD-1 and/or human VISTA in immunocompetent mice.

 

Request a quote here to get pricing, offers and hPD-1 model information by phone or email.

 

hPD-1 features

  • The PD-1 extracellular domain is entirely humanized
  • Physiological regulation and expression pattern of the human PD-1
  • Preservation of the target-ligand interaction
  • Fully functional mouse immune system
  • Lack of expression of the murine target gene, thus avoiding cross-reactivity

hPD-1 validation*

The model has been co-validated by Charles River, our partner of the precompetitive consortium of company leaders in immuno-oncology and immunotherapy.

A scientific poster was presented at the Tumour Models 2019 in Boston. Download poster

hPD-1 ICP model validation 1

hPD‑1 expression pattern recapitulates mPD‑1

hPD-1 and mPD-1 expression on αCD3/αCD28-activated splenocytes on (A) Tregs, conventional CD4+ at day 2 of culture and (B) on CD8+ T cells at the indicated time points.

hPD-1 ICP model validation 2

In vivo anti-tumor activity is observed in response to anti-PD-1 treatment in hPD‑1 mice

Survival of mice of indicated genotype implanted intracranially with GL261 murine glioma cells and treated with αhPD-1 or αmPD-1 (Mantel-Cox test: ***p<0.001).

* For more validation data please contact us.

Ready to be shipped to your lab

  • Cohorts available upon request
  • Studies can be carried out at your site or at your favorite CRO
  • VAF Elite/SOPF certification and worldwide delivery by professional breeders
  • Models provided with FTO on patent-protected technologies used for model generation


Are you looking for another target?
Follow this link humanized immune checkpoint (ICP) mouse models, or contact us.